Status:
COMPLETED
An Examination of Predictors of Indicators of Response to Letrozole 2.5 mg
Lead Sponsor:
University of Kansas
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
To assess the quantitative real time PCR results of oligonucleotide probes for a number of gene transcription products that may be useful as predictors or indicators of response to letrozole
Detailed Description
To assess the quantitative real time PCR results of oligonucleotide probes for a number of gene transcription products (PCNA, cyclin-D1, ER alpha, PR, pS2, 450 aromatase, bcl-2, bax, caspase-3, and VE...
Eligibility Criteria
Inclusion
- evidence of hyperplasia with/without atypia upon random periareolar fine needle aspiration of breast
- on hormone replacement therapy
- postmenopausal
- increased risk of developing breast cancer based on personal or family history
- never have taken aromatase inhibitors or selective estrogen receptor modulators in last six months
- women who have a high risk of breast cancer
- older than 18 years
Exclusion
- no anticoagulants
- no marked breast tenderness
- not pregnant or within twelve months of breast feeding/childbirth
Key Trial Info
Start Date :
January 1 2003
Trial Type :
OBSERVATIONAL
End Date :
July 1 2005
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00291109
Start Date
January 1 2003
End Date
July 1 2005
Last Update
September 16 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160